Columbia researcher uncovers gene that solidifies the link between macular telangiectasia type 2 (MacTel) and serine deficiency and points the way to effective treatment.

Columbia University is one of the leading programs in the United States conducting a groundbreaking Phase 2 clinical trial of an investigational gene therapy for dry age-related macular degeneration.

With the support of a major award from The Brown Foundation, Dr. Jeffrey M. Liebmann and his team have launched the Brown Glaucoma Genetics Initiative, a continuum of investigative and therapeutic projects with the aim of developing treatments for specific subtypes of the disease.

NewYork-Presbyterian/Columbia University Irving Medical Center recently unveiled an advanced mobile testing unit in an effort to reduce blindness-causing eye diseases in underserved neighborhoods.

The incidence of rhegmatogenous retinal detachment, the most common type of retinal detachment, has been reported to be between 6.3 and 18 per 100,000 each year.

Relatively rare, cancers of the eye require the expertise of an ocular oncologist with experience in the diagnosis, treatment, and management of ocular tumors.

Cataracts in children cause more visual impairment than any other form of treatable blindness and infantile and childhood cataracts affect approximately 3 out of 10,000 children.

A new era of collaboration in vision science has emerged in upper Manhattan linking the ophthalmology departments of NYP/CUMC and HHC.